Novo Nordisk A/S
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]
Read More
Disney’s next CEO, Chipotle’s traffic problem, government shutdown ends and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Wednesday. In addition to Disney’s Josh D’Amaro, there was another top dog announced yesterday: Penny the Doberman pinscher won best in show at the Westminster Kennel Club Dog Show. Stock futures are ticking higher this morning. The market is coming off […]
Read More
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant […]
Read More
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its 2026 forecast late Tuesday, sending shares tumbling. Novo Nordisk’s stock plummeted 18% in Copenhagen early Wednesday, tracking losses seen in its American depositary shares on Tuesday and more than wiping out gains seen so far […]
Read More
CNBC Daily Open: UBS posts strong earnings while Novo Nordisk’s U.S. shares crater on slowing growth
Sergio Ermotti, CEO of UBS, speaking on CNBC’s Squawk Box at the World Economic Forum in Davos, Switzerland on Jan. 20th, 2026. Oscar Molina | CNBC UBS fourth-quarter profit rose 56% year on year to $1.2 billion, beating expectations. The Swiss bank on Wednesday also announced plans for a $3 billion share buyback in 2026 […]
Read More
Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more
Check out the companies making headlines before the bell: Novo Nordisk — The maker of obesity drug Wegovy’s U.S. stock fell about 13% after unexpectedly warning that fiscal 2026 sales will be hurt by lower drug prices in the U.S. even as it anticipates more patients will use its popular GLP-1 drug. Novo Nordisk said […]
Read More
Novo Nordisk shares tumble after company forecasts sales declines this year
Novo Nordisk‘s U.S. shares plummeted Tuesday after the company said it sees sales and profit growth declining this year, hit by lower prices in the U.S. and loss of exclusivity for its blockbuster Wegovy and Ozempic in China, Brazil and Canada. The company published the forecast as it reported full-year 2025 sales, ahead of the […]
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]
Read More
Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that […]
Read More
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity […]
Read More